Affiliation:
1. Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China
Abstract
Introduction:
Paxlovid (nirmatrelvir/ritonavir) has received endorsement
from several guidelines for treating COVID-19 in adults, but its use in children is still
uncertain.
Objectives:
This study aimed to evaluate the safety and effectiveness of paxlovid in pediatric
patients in the pediatric intensive care unit (PICU).
Methods:
A retrospective analysis was performed on children with COVID-19. The children
who received paxlovid comprised the paxlovid group; otherwise, they were referred
to as the control group.
Results:
A total of 31 children were enrolled, with 12 and 19 participants assigned to the
paxlovid and control groups, respectively. Approximately 35% had received vaccination
against the novel coronavirus. The control group exhibited a significantly lower mean
age in comparison to the paxlovid group (p < 0.001). However, no significant differences
were observed between the groups in terms of other baseline data and biochemical
indexes at admission. However, on the fifth day of drug administration, the paxlovid
group exhibited a statistically significant decrease in temperature compared to the control
group (p < 0.05). Additionally, the paxlovid group exhibited a significantly shorter
conversion time to negativity for novel coronary genes in the respiratory tract (9.5 days)
compared to the control group (16 days, p < 0.05). The administration of paxlovid did
not result in any observed adverse reactions. Merely two patients exhibited a transient elevation
in liver enzyme levels.
Conclusion:
The application of paxlovid in critically ill pediatric patients with
COVID-19 can effectively control symptoms and promote virus clearance, demonstrating
efficacy and a relatively low-risk profile.
Publisher
Bentham Science Publishers Ltd.